Comprehensive analysis of expansive pharmacogenomic datasets is a daunting challenge. A thorough exploration of experimental results requires both statistical and annotative information. Therefore, appropriate analysis tools must bring a readily-accessible, flexible combination of statistics and biological annotation to the user's desktop. We present the Exploratory Visual Analysis (EVA) softwa...

Pharmacogenomics has identified important drug-gene interactions that affect the safety and efficacy of medications. Direct-to-consumer genetic testing, when first introduced, included some pharmacogenomic-related genes. The current landscape of pharmacogenomic direct-to-consumer testing is reviewed. Prior published reviews of the literature were updated through February 2017 and a scan of the ...

Pharmacogenomic biomarkers hold great promise for the future of medicine and have been touted as a means to personalize prescriptions. Genetic biomarkers for disease susceptibility including both Mendelian and complex disease promise to result in improved understanding of the pathophysiology of disease, identification of new potential therapeutic targets, and improved molecular classification o...

Personalized medicine is becoming a medical reality, as important genotype-phenotype relationships are being unraveled. The availability of pharmacogenomic data is a key element of individualized care. In this study, we explored genotype imputation as a means to infer important pharmacogenomic alleles from a regular commercially available genome-wide SNP array. Using these arrays as a starting ...

Pharmacogenomic biomarkers can optimize an individual’s therapy; however, the overall role of genetic factors in drug response remains uncertain. The majority of genetic variants currently used as clinical pharmacogenomic biomarkers affect drug metabolism and transport, while fewer biomarkers accurately predict drug response (pharmacodynamics). This article evaluates heritable aspects of drug t...

background: pharmacogenomics is the study of genetic variations among individuals to predict the probability that a patient will respond to single or multidrug chemotherapy. breast cancer is one of the most common cancers among women worldwide. treatment of breast cancer by application of biological rationales gives us the ability to match the correct pharmacology to individual tumour genetic p...

BACKGROUND The development of genotyping and genetic sequencing techniques and their evolution towards low costs and quick turnaround have encouraged a wide range of applications. One of the most promising applications is pharmacogenomics, where genetic profiles are used to predict the most suitable drugs and drug dosages for the individual patient. This approach aims to ensure appropriate medi...

We surveyed 10,303 United States physicians on where they obtain pharmacogenomic testing information. Thirty-nine percent indicated that they obtained this from drug labeling. Factors positively associated with this response included older age, postgraduate instruction, using other information sources, regulatory approval/ recommendation of testing, reliance on labeling for information, and per...

OBJECTIVE To explore the perceptions of health care professionals in examining the uses of pharmacogenomic data. METHODS A mailed questionnaire elicited respondent perceptions of how the use of pharmacogenomic information would impact the provision of health-related services (7-point scale: 7=strongly increase to 1=strongly decrease). Respondents were also asked to describe their level of agr...

This report describes two cases in which pharmacogenomic testing was utilized to guide medication selection for difficult to treat patients. The first patient is a 29-year old male with bipolar disorder who had severe akathisia due to his long acting injectable antipsychotic. The second patient is a 59-year old female with major depressive disorder who was not responding to her medication. In b...